Efforts to contain the novel coronavirus outbreak that sprang from Wuhan, China, in December are placing new challenges on the global pharmaceutical manufacturing infrastructure that has emerged in the 21st century.
In the immediate term, quarantines and travel restrictions are raising questions about the transport of drug products and ingredients to...





